Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Announces Changes to Board of Directors
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Black Diamond Therapeutics Announces CEO Transition
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX GTHX
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Tickers BDTX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.